Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.43 |
| ▸ | NMT2 | O60551 | 4/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18888077 | 0.93 | NMT1 (0.49) | NMT1NMT2TLR2SIRT2SIRT5 | |
| SCHEMBL18888079 | 0.89 | NMT1 (0.42) | NMT1NMT2TLR2OPRM1OPRD1 | |
| SCHEMBL19334631 | 0.88 | GLP1R (0.47) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL18888118 | 0.87 | NMT1 (0.44) | NMT1NMT2TLR2SIRT2SIRT5 | |
| SCHEMBL18888153 | 0.86 | GLP1R (0.43) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL16156114 | 0.79 | GLP1R (0.48) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL16948010 | 0.79 | ALDH1A1 (0.38) | SIRT5GLP1RNOD1 | |
| SCHEMBL16156153 | 0.78 | NMT1 (0.42) | NMT1NMT2TLR2OPRM1OPRD1 | |
| SCHEMBL18569179 | 0.74 | NOD1 (0.41) | NMT1NMT2TLR2OPRM1OPRD1 | |
| SCHEMBL27460520 | 0.73 | GLP1R (0.53) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145069-A1 | GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2017-05-25 | — | — | US | disclosed |
| US-20140303083-A1 | GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145069-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | NMT1 882/4885NMT2 1122/4885TLR2 1380/4885 |
| US-20140303083-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | NMT1 1096/4885NMT2 1365/4885TLR2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.